GeneDx Holdings Corp.
WGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $305 | $203 | $235 | $212 |
| % Growth | 50.8% | -13.7% | 10.6% | – |
| Cost of Goods Sold | $111 | $113 | $261 | $229 |
| Gross Profit | $194 | $90 | -$27 | -$17 |
| % Margin | 63.6% | 44.4% | -11.4% | -7.8% |
| R&D Expenses | $46 | $58 | $86 | $105 |
| G&A Expenses | $101 | $134 | $216 | $206 |
| SG&A Expenses | $168 | $195 | $338 | $319 |
| Sales & Mktg Exp. | $67 | $61 | $122 | $113 |
| Other Operating Expenses | $3 | $18 | $216 | $6 |
| Operating Expenses | $218 | $271 | $641 | $430 |
| Operating Income | -$23 | -$181 | -$668 | -$446 |
| % Margin | -7.6% | -89.2% | -284.5% | -210.3% |
| Other Income/Exp. Net | -$29 | $4 | $70 | $201 |
| Pre-Tax Income | -$53 | -$177 | -$598 | -$245 |
| Tax Expense | -$0 | -$1 | -$49 | $0 |
| Net Income | -$52 | -$176 | -$549 | -$245 |
| % Margin | -17.1% | -86.8% | -233.9% | -115.6% |
| EPS | -1.94 | -7.23 | -53.63 | -74.93 |
| % Growth | 73.2% | 86.5% | 28.4% | – |
| EPS Diluted | -1.94 | -7.23 | -53.63 | -74.93 |
| Weighted Avg Shares Out | 27 | 24 | 10 | 3 |
| Weighted Avg Shares Out Dil | 27 | 24 | 10 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $3 | $0 |
| Interest Expense | $3 | $0 | $3 | $3 |
| Depreciation & Amortization | $22 | $34 | $59 | $22 |
| EBITDA | -$1 | -$136 | -$398 | -$221 |
| % Margin | -0.4% | -67.4% | -169.7% | -104% |